Real-World Evidence

16: Clinical Outcome of Patients with Primary Metastatic Renal Cell Carcinoma Carefully Selected for Cytoreductive Nephrectomy: A Nationwide Real-World Data

17: Patient characteristics, treatment patterns and outcomes for patients with renal cell carcinoma (RCC) in England

18: Optimal Duration of Frontline Immunotherapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)

19: Real World Experience (RWE) of Ipilimumab and Nivolumab compared to Pembrolizumab and Axitinib in Advanced Renal Cell Carcinoma (RCC)

20: A UK real-world observational study of avelumab + axitinib (A+Ax) in advanced renal cell carcinoma (RCC): exploratory analysis of 24-month interim results in patients with non-clear cell histology

21: Real-world recurrence patterns in Danish renal cell carcinoma patients

22: Baseline characteristics from the real-world CARINA study of patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy

23: Role of cytoreductive nephrectomy in metastatic RCC, single institution experience

24: Real-world outcomes of nivolumab (NIVO) + ipilimumab (IPI) in patients with previously untreated clear cell advanced renal cell carcinoma (aRCC) in France.

25: 4-weekly avelumab administration plus axitinib in patients with metastatic renal cell carcinoma: A single centre analysis of patient outcomes

26: Anticoagulant treatment and thromboembolic events prior to diagnosis of renal cell carcinoma: Impact on stage distribution